A Regulated Digital Health Platform that Accelerates Time to Market and Minimizes Risk

Our BrightInsight Platform is built under a Quality Management System to support and optimize up to Class III regulated drugs, devices, software, connected surgical equipment and Digital Therapeutics through integrated data and actionable insights

Homepage icons scalable turnkey solution

A scalable, turnkey solution

Hit the ground running with our managed service model, modular platform architecture and foundational capabilities.

Homepage icons next level intelligence

Next-level intelligence

Our integrated data management transforms drug and device data into powerful real-time insights.

Homepage icons medical grade security

Medical-grade security, privacy and compliance

Our advanced quality, security, privacy and compliance processes and tools give you peace of mind.

Learn More

BrightInsight Announces $101M in Series C Funding!

Led by General Catalyst, the Financing will Fuel BrightInsight’s Hypergrowth as the Leading Global Regulated Digital Health Platform for Biopharma and Medtech

Learn More
series C funding $101 million

AstraZeneca Launches Chronic Disease Management Solution on BrightInsight Platform

Learn More
BI Astra Zeneca logos screens
BrightInsight brand arrows

Download our latest Industry Brief with Biopharma Dive to hear from industry experts on how to approach the regulatory strategy for your underlying digital health infrastructure.

Using a regulated infrastructure alleviates regulatory concerns as you’re developing your product over years and years. You can be confident that from an infrastructure standpoint, you’ll be compliant.

- Bradley Merrill Thompson, Epstein Becker & Green, P.C.

Blog

Digital Health C-Suite Video Series

Read More

BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases

CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment.

Learn More
Homepage split BICSL Behring logos
arrows graphic

COVID-19’s Impact on Digital Health

covid bar graph
89.9%
Yes
11.1%
No

Almost 9 out of 10 biopharma leaders say COVID-19 has increased their focus on digital health.

Learn More

Careers

Join our award-winning team

View Jobs

Frost & Sullivan Names BrightInsight its 2020 Global Entrepreneurial Company of the Year for Healthcare IoT Solutions

Learn More
Homepage split award frost sullivan

How Roche and BrightInsight Launched a Software as a Medical Device in 6 months’ Time

Download our webinar to hear Paul Upham, Head of Smart Devices at Roche/Genentech, discuss how Roche launched a regulated SaMD dosing calculator for treating Hemophilia A.

Download